TY - JOUR
T1 - In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
AU - Skoglund, Karin
AU - Richter, Johan
AU - Olsson-Strömberg, Ulla
AU - Bergquist, Jonas
AU - Aluthgedara, Warunika
AU - Ubhayasekera, S J Kumari A
AU - Vikingsson, Svante
AU - Svedberg, Anna
AU - Söderlund, Stina
AU - Sandstedt, Anna
AU - Johnsson, Anders
AU - Aagesen, Jesper
AU - Alsenhed, Jonas
AU - Hägg, Staffan
AU - Peterson, Curt
AU - Lotfi, Kourosh
AU - Gréen, Henrik
PY - 2016
Y1 - 2016
N2 - CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.
AB - CYP3A metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) patients. The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib in CML patients.
U2 - 10.1097/FTD.0000000000000268
DO - 10.1097/FTD.0000000000000268
M3 - Article
C2 - 26693810
SN - 0163-4356
VL - 38
SP - 230
EP - 238
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 2
ER -